{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-003981","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.346370+00:00","generated_at":"2026-05-16T15:47:59.798313+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Silexion receives positive BfArM feedback on Phase 2/3 trial design for SIL204 in pancreatic cancer","bullets":["BfArM written Scientific Advice supports proposed Phase 2/3 study design, dosing, patient population, and CMC.","Phase 2/3 trial initiation for SIL204 planned for Q2 2026, pending regulatory clearance.","Regulatory submissions expected in Israel by end of Q4 2025 and in Germany during Q1 2026.","SIL204 targets KRAS-driven locally advanced pancreatic cancer; momentum builds toward clinical launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-003981","json":"https://secwatch.observer/filing/0001178913-25-003981.json","markdown":"https://secwatch.observer/filing/0001178913-25-003981.md","text":"https://secwatch.observer/filing/0001178913-25-003981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003981/0001178913-25-003981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325003981/zk2534079.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:47:59.798313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}